Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Karyopharm Therapeut (NQ: KPTI )

0.8494 +0.0044 (+0.52%)
Streaming Delayed Price Updated: 3:45 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Karyopharm Therapeut

< Previous 1 2 3 4 5 6 Next >
Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript
KPTI earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Karyopharm Therapeutics (KPTI) Q2 2024 Earnings Call Transcript
KPTI earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
KPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Beats Revenue for Q2 2024
KPTI stock results show that Karyopharm Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
These are the biotech stocks to buy for a massive rally in the coming quarters on the back of positive clinical progress. 
Via InvestorPlace
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Karyopharm Therapeutics's Earnings: A Preview
Via Benzinga
Earnings Preview For Karyopharm Therapeutics
Via Benzinga
6 Analysts Have This to Say About Karyopharm Therapeutics
Via Benzinga
Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript
KPTI earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
KPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Misses Revenue for Q1 2024
KPTI stock results show that Karyopharm Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript
KPTI earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
4 Analysts Have This to Say About Karyopharm Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Karyopharm Therapeutics (KPTI) Q3 2023 Earnings Call Transcript
KPTI earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 59 companies achieved new lows for the year. 
Via Benzinga
Karyopharm Therapeutics (KPTI) Q2 2023 Earnings Call Transcript
KPTI earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Karyopharm's Selinexor Shows Progression-Free Survival of 27.4 Months In Endometrial Cancer With Certain Mutation
Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced the presentation of updated exploratory subgroup analyses from the SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's trading, 46 companies set new 52-week lows. 
Via Benzinga
CMG Stock Alert: Chipotle Announces International Expansion Plan
Chipotle Mexican Grill (CMG) stock is in the news Tuesday after the restaurant chain announced plans for an international expansion. 
Via InvestorPlace
Why Are Karyopharm Therapeutics Shares Gaining Today?
Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares are trading higher after the FDA granted Fast Track Designation to the development program of selinexor for myelofibrosis, including primary... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is CEL-SCI (CVM) Stock Down 23% Today?
CEL-SCI (CVM) stock is dropping on Tuesday after the biotechnology company announced details of a public share offering. 
Via InvestorPlace
Why Is Masimo (MASI) Stock Down 30% Today?
Masimo (MASI) stock is taking a beating on Tuesday after the patient monitoring tech company released preliminary earnings for Q2 2023. 
Via InvestorPlace
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's... 
Via Benzinga
Why Is Karyopharm Therapeutics (KPTI) Stock Up 21% Today?
Karyopharm Therapeutics (KPTI) stock is climbing higher on Tuesday after getting fast-track designation for its myelofibrosis treatment. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS